BNTX

Moderna’s cancer vaccine cut melanoma recurrence or death risk by 42%. Investors are unsure if the benefit extends to other cancers.

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.

BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in…

BioNTech and Gilead are testing pumitamig with sacituzumab govitecan as first‑line therapy for advanced triple‑negative breast cancer. The partnership aims to combine a bispecific immunomodulator with an antibody drug conjugate.

BioNTech’s share price has fluctuated, with a 66.9% drop over five years. Investors are questioning whether the current valuation matches its oncology revenue base.

Moderna is adding RSV, flu, and combination vaccines to its lineup. Competition may limit how much this reduces its dependence on COVID products.

MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m.